ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ESMO 2024 – iTeos TIGIT meets its efficacy criteria
But the Galaxies Lung-201 trial features notable omissions, plus toxicity.
ESMO 2024 – Opdualag comes under fire
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
ESMO 2024 – Nuvalent looks beyond its late-line Alkove
Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.
ESMO 2024 – degraders disappoint again
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
